Xencor | XNCR - Current Assets


Xencor reported $523.21M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Biogen USD 7.58B 278.7M Sep/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Cytokinetics USD 1.21B 369.02M Jun/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
MacroGenics USD 321.69M 139.16M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Novartis USD 27.35B 744M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Xencor USD 523.21M 40.36M Jun/2026